These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 16491624)

  • 1. New agents and new formulations for the treatment of ovarian cancer.
    Sabbatini P
    Clin Adv Hematol Oncol; 2005 Nov; 3(11):840-2. PubMed ID: 16491624
    [No Abstract]   [Full Text] [Related]  

  • 2. Complete remission of recurrent ovarian clear cell carcinoma by chemotherapy with bevacizumab, trabectedin and oxaliplatin.
    Takano M; Ikeda Y; Kudoh K; Kita T; Sasaki N; Kikuchi Y
    J Obstet Gynaecol Res; 2013 Apr; 39(4):872-5. PubMed ID: 23167774
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lack of reliability of CA125 response criteria with anti-VEGF molecularly targeted therapy.
    Markman M
    Cancer; 2008 Nov; 113(10):2832-3; author reply 2833-4. PubMed ID: 18846540
    [No Abstract]   [Full Text] [Related]  

  • 4. Cediranib aims for a comeback.
    Schmidt C
    J Natl Cancer Inst; 2015 Mar; 107(3):. PubMed ID: 25745013
    [No Abstract]   [Full Text] [Related]  

  • 5. Monoclonal antibodies targeting vascular endothelial growth factor: current status and future challenges in cancer therapy.
    Hsu JY; Wakelee HA
    BioDrugs; 2009; 23(5):289-304. PubMed ID: 19754219
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Angiogenesis inhibition in the treatment of lung cancer.
    Vokes E; Herbst R; Sandler A
    Clin Adv Hematol Oncol; 2006 Nov; 4(11 Suppl 23):1-10; quiz 11-2. PubMed ID: 17143257
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting the future in head and neck cancer.
    Brizel DM
    Lancet Oncol; 2009 Mar; 10(3):204-5. PubMed ID: 19261251
    [No Abstract]   [Full Text] [Related]  

  • 8. Bevacizumab and erlotinib show promise for kidney cancer.
    Lindsey H
    Lancet Oncol; 2006 Jan; 7(1):15. PubMed ID: 16408368
    [No Abstract]   [Full Text] [Related]  

  • 9. Combining targeted agents: blocking the epidermal growth factor and vascular endothelial growth factor pathways.
    Sandler A; Herbst R
    Clin Cancer Res; 2006 Jul; 12(14 Pt 2):4421s-4425s. PubMed ID: 16857821
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of bevacizumab in recurrent, platinum-sensitive ovarian cancer.
    Gubbi A; Kendrick JE; Finkler NJ
    Expert Rev Anticancer Ther; 2014 Oct; 14(10):1105-13. PubMed ID: 25189201
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Consolidation for ovarian cancer in remission.
    Sabbatini P; Spriggs DR
    J Clin Oncol; 2006 Feb; 24(4):537-9. PubMed ID: 16446325
    [No Abstract]   [Full Text] [Related]  

  • 12. Bevacizumab in the treatment of ovarian cancer.
    Han ES; Monk BJ
    Expert Rev Anticancer Ther; 2007 Oct; 7(10):1339-45. PubMed ID: 17944559
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lack of reliability of CA125 response criteria with anti-VEGF molecularly targeted therapy.
    Azad NS; Annunziata CM; Steinberg SM; Minasian L; Premkumar A; Chow C; Kotz HL; Kohn EC
    Cancer; 2008 Apr; 112(8):1726-32. PubMed ID: 18300236
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bevacizumab and erlotinib: a promising new approach to the treatment of advanced NSCLC.
    Herbst RS; Sandler A
    Oncologist; 2008 Nov; 13(11):1166-76. PubMed ID: 18997180
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bevacizumab plus cyclophosphamide in heavily pretreated patients with recurrent ovarian cancer.
    Chura JC; Van Iseghem K; Downs LS; Carson LF; Judson PL
    Gynecol Oncol; 2007 Nov; 107(2):326-30. PubMed ID: 17706754
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bevacizumab in breast cancer: the best is yet to come?
    Puhalla S; Brufsky A
    Oncology (Williston Park); 2009 Apr; 23(4):332, 335. PubMed ID: 19476262
    [No Abstract]   [Full Text] [Related]  

  • 17. The risk of gastrointestinal perforation and/or fistula in patients with recurrent ovarian cancer receiving bevacizumab compared to standard chemotherapy: a retrospective cohort study.
    Sfakianos GP; Numnum TM; Halverson CB; Panjeti D; Kendrick JE; Straughn JM
    Gynecol Oncol; 2009 Sep; 114(3):424-6. PubMed ID: 19552944
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New drugs for ovarian cancer.
    Kaye SB
    Clin Adv Hematol Oncol; 2008 Feb; 6(2):91-3. PubMed ID: 18347558
    [No Abstract]   [Full Text] [Related]  

  • 19. Phase I study of cetuximab, erlotinib, and bevacizumab in patients with advanced solid tumors.
    Lin CC; Calvo E; Papadopoulos KP; Patnaik A; Sarantopoulos J; Mita AC; Preston GG; Mita MM; Rodon J; Mays T; Yeh IT; O'Rourke P; Takimoto CH; Dancey JE; Chen H; Tolcher AW
    Cancer Chemother Pharmacol; 2009 May; 63(6):1065-71. PubMed ID: 18795291
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Avoiding bevacizumab related gastrointestinal toxicity for recurrent ovarian cancer by careful patient screening.
    Simpkins F; Belinson JL; Rose PG
    Gynecol Oncol; 2007 Oct; 107(1):118-23. PubMed ID: 17658587
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.